Nxera Pharma Secures $3M Milestone from Centessa for Orexin Receptor Drug
Event summary
- Nxera Pharma to receive $3M milestone payment from Centessa Pharmaceuticals for ORX489 development.
- ORX489 is an orally administered orexin receptor 2 (OX2R) agonist for neuropsychiatric disorders.
- Payment recognized as revenue in Q1 2026.
- Milestone triggered by early development progress in Centessa's program.
The big picture
This milestone underscores the strategic value of Nxera's NxWave™ GPCR drug discovery platform in attracting global pharma partnerships. The $3M payment reflects growing industry interest in novel neuropsychiatric treatments, particularly those targeting orexin receptors. Nxera's ability to monetize its platform through such deals positions it as a key player in the high-value APAC and global biopharma markets.
What we're watching
- Pipeline Progress
- Whether Centessa can advance ORX489 through clinical development and trigger further milestones.
- Revenue Impact
- How this payment contributes to Nxera's financial performance in 2026.
- Partnership Dynamics
- The pace at which Nxera's collaborations generate additional milestone payments.
Related topics